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HBsAg-negative donors sometimes contained HBV DNA. With im-
provements in HBV DNA ampliﬁcation technology, we are now
approaching single genome detection capabilities. When coupled
with enhancements in the sensitivity and speciﬁcity of assays
for anti-HBc and HBsAg, previous misinterpretations are being
revised, and we now have a better understanding of risk.
Most experts would concur that blood collected during the early
seronegative window period of HBV (when only HBV DNA is
present) is highly infectious. This risk appears to be greater
during the expansion phase of HBV DNA than that which is seen
during the recovery phase of acute disease when anti-HBs may
complex with the virus leading to modulation of the disease pro-
cess and a reduction in the risk of transmission despite detection
of HBV DNA.
Following the uneven implementation of ultrasensitive nucleic
acid testing of blood donors in various regions of the world,
the residual risk of HBV was found to be inconstant with inci-
dence/window period rates varying from 1:350,000 in the US and
Europe to 1:50,000 in Japan and to 1:5000 or lower in Southeast
Asia and Pakistan. As interest in evaluating the residual yield of
HBV DNA positive donations in HBsAg and anti-HBc negative donor
samples (seronegative window period donations) has intensiﬁed,
some unexpected ﬁndings have emerged. For example, from Jan-
uary 2008 to January 2009, the American Red Cross (ARC) tested
3,694,858 units of blood for HBV DNA either in minipools of 16
donations (84.4%) or as individual donations (16.6%) (Stramer et
al, 2009). HBV DNA was detected in 9 donors (1:410,000) with
only one of these (11%) requiring individual testing (ID-NAT) for
detection (i.e., not detected by minipool testing). Enrollment
and follow-up data were not available for 2 of the donors. Of
the 7 remaining donors in whom data were available, 5 were
in vaccinated individuals. Four of these were anti-HBs positive
in the index donation (anti-HBs concentrations from 3-43 IU/L)
whereas one became anti-HBs positive within 45 days. Viral loads
in these index donations were low and ranged from 100-200
copies/mL (∼16-33 IU/mL). Six of the 7 donors became IgM
anti-HBc positive and only one was a ﬁrst-time donor. Of interest
was the fact that 5 of the donors were subsequently discovered
to have sexual partners who were HBV chronic carriers with HBV
DNA viral loads >108 copies/mL in the 4 samples that were
available for testing. Among the 7 genotyped donor isolates, 4
represented genomes not typically found in the US (B2, C2, D3,
F1; all from vaccinated donors) while 3 were primarily of US
origin (A2). The infected partners associated with 4 of the donors
had the same subgenotype, and full genome sequences veriﬁed
the close relationship between these isolates.
Among the 5 vaccinated donors who were followed for 119-320
days, none developed ALT levels above 19 U/L or complained of
symptoms and all became HBV DNA negative, thereby conﬁrming
the effectiveness of vaccination in preventing clinical disease.
Only 3 of the 7 HBV DNA positive donors developed detectable
HBsAg. A group in Taiwan (Wang et al, 2002) observed the devel-
opment of HBV DNA in three vaccinated children within a week
after receiving blood that resulted in an aborted subclinical
infection similar to what was seen in the ARC donors. It is note-
worthy that both unvaccinated ARC donors who were followed
for at least 228 days developed signiﬁcant ALT abnormalities (119
U/L and 640 U/L).
An important issue is whether anti-HBs in conjunction with a
low viral load in a donor is sufﬁcient to prevent transmission
of HBV to a recipient. There are several studies which suggest
that this is a rare event. Mosley et al (1995) found no HBV
transmission associated with a donor whose anti-HBs values were
at least comparable to a level of 15 IU/L regardless of anti-HBc
status. Satake et al (2007) detected no infections in 22 HBV DNA
positive components that contained anti-HBs compared to 10 in-
fections that occurred among 37 components devoid of anti-HBs
(27%). Moreover, Aach et al (1974) were unable to detect any
transmission from HBV immune donors. Dreier and coworkers
(2004) and Gerlich (2006) failed to document transmission of HBV
from donors who were HBV DNA positive at levels <260 IU/mL,
but whose blood contained signiﬁcant levels of anti-HBs (>1000
IU/L). Conversely, low levels of anti-HBs (<75 IU/L) in HBV DNA
containing blood may carry a risk of transmission leading to
acute hepatitis in a recipient (Levicnik-Stezinar et al, 2008).
Fortunately, fulminant hepatitis is virtually unheard of following
posttransfusion hepatitis B.
In summary, nucleic acid testing is capable of detecting HBV
DNA in the absence of HBsAg and anti-HBc in a limited number
of donors with a yield that approaches ∼1:410,000 donors. The
issue of transmissibility from window period donations exists at
some ﬁnite level in unvaccinated donors in which the yield is
∼1:690,000. The public health beneﬁts of HBV NAT in blood banks
remain unknown but are likely to be marginal at considerable
cost in the US and Europe, but necessary in countries where the
disease is endemic.
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The immunosuppression by chemotherapy or immunosuppressive
therapy in chronic hepatitis B virus (HBV) infection is an in-
creasing risk for reactivation of hepatitis B and may lead to
acute hepatitis, chronic hepatitis, or even fulminant hepatitis
and death. Several studies have shown a signiﬁcant beneﬁt by
antiviral therapy with lamivudine to avoid reactivation, and the
prophylaxis with antiviral agents should be superior to therapy of
reactivation.
A rational approach to avoid the reactivation hepatitis B in these
patients has been developed, including (a) the evaluation of
HBV markers and liver condition in all patients before starting
immunosuppressive therapies; (b) the vaccination to patients
without detection of HBsAg or without sufﬁcient anti-HBs-titer;
(c) the treatment with antiviral agents of chronic hepatitis B
patients; (d) the prophylaxis use of antiviral agents such as
lamivudine in all HBsAg positive carriers; (d) the biochemical,
HBsAg and HBV DNA monitoring in subjects with HBsAg negative
and anti-HBc positive, or in subjects with markers of previous
contact with HBV; (e) the prophylaxis use of antiviral agents
before intense immunosuppression such as bone marrow trans-
plantation if anti-HBc positive, independent from HBsAg result.
Lamivudine has been approved to be effective and safe in
the management of immunosuppressive patients, other nucleo-
side analogues (telbivudine, entecavir) or nucleotide analogues
(adefovir dipivoxil, tenofovir) are potential candidates in this
situation, but larger experiences are yet missing.
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Resistance in Mycobacterium tuberculosis arises from man-made
selection of genetic mutants that result from spontaneous chro-
mosomal alterations. Thus, drug-resistant tuberculosis (TB) is
generally due to inappropriate treatment regimen, poor drug
quality, erratic drug supply and poor patient adherence to treat-
ment, reﬂecting failure in the implementation of an effective
TB control programme. Multidrug-resistant TB (MDR-TB) usually
denotes bacillary resistance to at least isoniazid and rifampicin
in vitro. Directly observed treatment, short-course (DOTS) is a
cost-effective strategy for TB control. Proper implementation of
the DOTS strategy should achieve a high cure rate for disease
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and curtail the development of drug resistance. Innovations in
reinforcement of this strategy should further facilitate its deliv-
ery and enhance its effectiveness. However, established MDR-TB
is notoriously difﬁcult to treat, and necessitates the use of alter-
native speciﬁc anti-TB chemotherapy regimens. These regimens
comprise combination use of second-line and third-line anti-TB
drugs, that are generally more costly and toxic, and have to
be given for longer durations – usually in the range of 18–24
months. The ﬂuoroquinolones, better tolerated by patients, have
a pivotal role in MDR-TB treatment. Optimal delivery of these
treatment regimens mandates a programmatic basis which is now
included under the Stop-TB Drug-Resistance Programme(s). The
key components embrace political commitment, quality-assured
drug susceptibility testing, reliable supply of quality drugs, de-
livery of chemotherapy under directly observed settings, and a
sound recording and reporting system to monitor the individual
treatment outcome of patient and overall performance of the
TB control programme. Adjunctive surgery in selected MDR-TB
patients help to improve their treatment success. Further ex-
ploration is required regarding the use of immunotherapy. The
recent emergence of extensively drug-resistant TB (XDR-TB),
representing MDR-TB with additional bacillary resistance to ﬂuo-
roquinlones and one or more of the second-line injectable drugs –
kanamycin, amikacin and capreomycin, poses a serious challenge
to the global control of TB. Given the escalating size of the
problem of MDR-TB and XDR-TB worldwide, gigantic instillation
of resources is required for control of this formidable challenge,
largely through more accurate and rapid drug susceptibility
testing (especially for rifampicin and ﬂuoroquinolone), regular
drug-resistance surveillance, development of new anti-TB drugs
and other therapeutic modalities, intensive infection control, es-
pecially in HIV care settings, as well as strengthening of currently
functioning DOTS and Drug-Resistance Programmes.
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Objective: In order to take an insight into the treatment of
AIDS and tuberculosis (TB) co-infection, we made a retrospective
study in 9 hospitals in mainland China.
Method: According to the uniﬁed questionary, 241 cases with
such co-infection were enrolled and the data with respect to
therapy and prognosis were analysed.
Result: Pulmonary TB accounted for 59.3%, extra pulmonary TB
for 21.2% and both for 19.5% of the patients. 76.8% of the 241
cases had a CD4 cell count<200 and 58.5%<100. 80.5% of the pa-
tients were treated with anti-tuberculosis medication and 69.7%
with highly active antiretroviral therapy. The regimen of anti-TB
was comprised of two-stage medication. The ﬁrst stage includes
INH, RFP, PZA and EMB while the second stage medication uses
INH and RFP. 203 (84.2%) were still alive and 38 (15.8%) died.
Conclusion: The combination regimen of many anti-TB agents
is potent to curing AIDS/TB co-infection. Generally, 4 anti-TB
agents used in ﬁrst stage for two monthes and 2 drugs used for
anti-TB in second stage for 4 monthes. If the tuberculosis was not
cured by the above regimen, the treatment of 2 agents regimen
should last for 7 monthes. The mortality (15.8%) was high even
with HAART and anti-tuberculosis therapy.
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The emergence of extensively drug resistant tuberculosis (XDR-
TB) strains among multi drug resistant tuberculosis (MDR-TB)
patients is widely considered as a serious threat to global TB
control. The diagnosis of XDR-TB is hampered by the absence of
effective and rapid diagnostic techniques for antimycobacterial
susceptibility testing especially in high-burden countries. The
advances in molecular technologies (eg. PCR, reverse hybridiza-
tion and DNA sequencing) represents a rapid diagnostic tool
due to their superior accuracy and cost-effectiveness in the de-
tection of mutations associated with drug resistance. Multiplex
allele-speciﬁc (MAS)-PCRs of mabA (3-ketoacyl reductase) and
katG (catalase-peroxidase) genes identify isoniazid resistance
while rifampin and oﬂoxacin resistance can be detected by PCR-
sequencing of rpoB (RNA polymerase β–subunit) and gyrA (gyrase
A) genes respectively. Direct detection of drug resistance asso-
ciated mutations in mabA, katG, rpoB, and gyrA genes indicate
potential application for rapid diagnosis of XDR-TB, resulting in a
net time gain of 1 to 2-months over conventional antimycobac-
terial susceptibility testing so that early initiation of anti-TB
therapy and management of patients can be initiated.
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Understanding of pharmacokinetic-pharmacodymic (PK-PD) prin-
ciples has revolutionized our understanding of anti-infective
dosing design. Apart from recognizing the pharmacokinetic prop-
erties (absorption, distribution, metabolism and excretion) of
an antibiotic, the pharmacodymics (such MIC distribution), the
PK-PD interactions such as concentration dependency and time
dependency are all of paramount importance in the design of
appropriate therapy. In the treatment of tuberculosis, as the
treatment duration is usually prolonged, ensuring compliance is
often problematic. Poor compliance will lead to failure of treat-
ment, relapse of disease, and emergence of multi-drug or even
extended-drug resistance. The recognition of speciﬁc property of
a drug, such as persistent effect (also known as post-antibiotic
effect) allows design of single daily dose, or even extended
interval dosing regimen. In vitro models, animal models and clin-
ical trials have ﬂourished in recent years. Rifampicin, isoniazid,
pyrazinamide, ﬂuoroquinolones, oxazolidinone all have individ-
ual PK-PD characteristics in terms of MIC90, Cmax/MIC and AUIC.
These had lead to the development of possible twice weekly or
even weekly regimens, as well as deﬁning mutation selection
window and its protection by the use of appropriate combination
therapy. Improvement in the understanding of these treatment
strategies, will not only maximize the therapeutic efﬁcacy, but
also improve compliance and also long term treatment outcomes.
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Identiﬁcation of latent TB infection (LTBI) is an important health
policy issue. In BCG vaccination countries, however, tuberculin
skin test (TST) is difﬁcult to be used as a predictor of TB infec-
tion. Recent application of interferon-γ blood tests has improved
the diagnosis. In this study, we applied and compared these tests
to identify the latent TB infection.
Materials and Methods: This was a prospective, double-
matched, cohort study in which 32 ESRD patients and 32 age-
matched, healthy controls were enrolled. The TST and two new
interferon-γ blood tests, QuantiFERON-TB Gold QFT-G) and T-
SPOT.TB (ELISPOT), were performed. The subjects were followed
